Ann: RELINT: FPH: Disclosure Director Relevant Interests

• Release Date: 09/09/15 08:31
• Summary: RELINT: FPH: Disclosure Director Relevant Interests
• Price Sensitive: No
• Download Document  5.05KB

					FPH
09/09/2015 08:30
RELINT
NOT PRICE SENSITIVE
REL: 0830 HRS Fisher & Paykel Healthcare Corporation Limited

RELINT: FPH: Disclosure Director Relevant Interests

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  8-Sep-15
Date of last disclosure:   23-Dec-14

Director or senior manager giving disclosure
Full name(s):  Michael Grenfell DANIELL
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  "Managing Director/
Chief Executive Officer"

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  (a) Ordinary Shares (b)
Beneficial Ownership of Options to acquire Ordinary Shares (c) Beneficial
Ownership of Performance Share Rights over Ordinary Shares
For that relevant interest-
Number held in class before (a) exercise; (b) acquisition:  (a) 884,879 (b)
750,000 (c) 110,000
Number held in class after (a) exercise; (b) acquistion:  (a) 914,879 (b)
830,000  (c) 110,000
Current registered holder(s):  (a) Michael Grenfell DANIELL, Daniell Family
Trust (b) and (c) Michael Grenfell DANIELL
Registered holder(s) once transfers are registered:  (a) Michael Grenfell
DANIELL, Daniell Family Trust (b) and (c) Michael Grenfell DANIELL

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  (a) 3/09/2015 (b) 8/09/2015 (c) 8/09/2015
Nature of transaction:  (a) Exercise of 30,000 Performance Share Rights
under the Company's Performance Share Rights Scheme (b) Issue of 80,000
Options under the Company's Share Option Scheme (c) Issue of 30,000
Performance Share Rights under the Company's Performance Share Rights Scheme
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  (a)
NZ$Nil (b) NZ$Nil (c) NZ$Nil
Number of financial products to which the transaction related:  (a) 30,000
(b) 80,000 (c) 30,000
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not applicable
Date of the prior written clearance (if any):  Not applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
Note: Ordinary Shares held by Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited (of which Michael Grenfell Daniell is a director)
will no longer be disclosed following the determination by the Company that
such holding does not constitute a relevant interest for Michael Grenfell
Daniell.
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Certification
End CA:00269843 For:FPH    Type:RELINT     Time:2015-09-09 08:31:01